Share on StockTwits

InterMune (NASDAQ:ITMN) will release its earnings data on Tuesday, May 20th. Persons interested in registering for the company’s earnings conference call can do so using this link.

InterMune (NASDAQ:ITMN) last released its earnings data on Thursday, May 1st. The company reported ($0.59) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.62) by $0.03. The company had revenue of $30.30 million for the quarter, compared to the consensus estimate of $28.24 million. During the same quarter in the prior year, the company posted ($0.64) earnings per share. The company’s quarterly revenue was up 188.6% on a year-over-year basis. On average, analysts expect InterMune to post $-2.35 EPS for the current fiscal year and $-0.86 EPS for the next fiscal year.

InterMune (NASDAQ:ITMN) opened at 34.31 on Monday. InterMune has a one year low of $9.27 and a one year high of $38.73. The stock’s 50-day moving average is $31.9 and its 200-day moving average is $21.81. The company’s market cap is $3.393 billion.

Several analysts have recently commented on the stock. Analysts at Jefferies Group raised their price target on shares of InterMune from $20.00 to $22.00 in a research note on Friday, May 2nd. On the ratings front, analysts at Stifel Nicolaus reiterated a “buy” rating on shares of InterMune in a research note on Friday, May 2nd. They now have a $45.00 price target on the stock, up previously from $43.00. Finally, analysts at Goldman Sachs upgraded shares of InterMune from a “neutral” rating to a “buy” rating in a research note on Tuesday, March 11th. They now have a $45.00 price target on the stock, up previously from $40.00. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $37.40.

In other InterMune news, VP Sean Nolan sold 2,644 shares of InterMune stock in a transaction dated Thursday, May 8th. The stock was sold at an average price of $35.85, for a total transaction of $94,787.40. Following the transaction, the vice president now directly owns 72,556 shares in the company, valued at approximately $2,601,133. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

InterMune, Inc (NASDAQ:ITMN), is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.